Comparison of the Efficacy of Vaginal Hyaluronic Acid to Estrogen for the Treatment of Vaginal Atrophy in Postmenopausal Women: A Systematic Review

被引:3
作者
Albalawi, Nada Saleh [1 ]
Almohammadi, Maram Ati [2 ]
Albalawi, Ahmad Raja [3 ]
机构
[1] Minist Hlth, Geriatr Dept, King Fahad Specialist Hosp, Tabuk, Saudi Arabia
[2] Minist Hlth, Acad Affairs & Training Adm, Training Dept, Tabuk, Saudi Arabia
[3] Minist Hlth, Diabet & Endocrine Dept, King Fahad Specialist Hosp, Tabuk, Saudi Arabia
关键词
postmenopausal; estrogen; hyaluronic acid; dyspareunia; atrophic vaginitis; GENITOURINARY SYNDROME; TREATMENT OPTIONS; MENOPAUSE; SAFETY;
D O I
10.7759/cureus.44191
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Topical estrogen is effective for treating postmenopausal vaginal atrophy. However, there is a potential risk of estrogen-related adverse effects. There is a need for finding effective non- hormonal treatment for vaginal atrophy. The topical application of moisturising agents, such as hyaluronic acid (HA), represents a promising non-hormonal treatment for the relief of vaginal atrophy. This study aimed to summarize the evidence regarding the efficacy of topical HA compared to topical estrogen in postmenopausal women with vaginal atrophy. The literature search covered English-published studies from database inception till February 2023. The search included the electronic databases of MEDLINE/PubMed, Cochrane Library, Web of Science, ProQuest, and Scopus, using the terms "Hyaluronic Acid" AND "Postmenopause" AND "Vagina" AND "Atrophy". Due to the diversity in reporting outcomes, meta-analysis was not feasible. A narrative synthesis with a systematic approach was conducted by vote counting of studies that included a direct comparison between topical HA and topical estrogen. Six studies were included. Intra-group comparisons showed that both interventions were significantly effective in alleviating the symptoms of vaginal atrophy and dyspareunia as well as improving vaginal pH and cell maturation index. However, inter-group comparisons in most studies showed that estrogen was superior to HA in relieving vaginal symptoms and improving vaginal pH, dyspareunia, and the cell maturation index. There is no evidence to show the superiority of HA to estrogen in the treatment of postmenopausal vaginal atrophy. However, the therapeutic efficacy of HA seems to be comparable to estrogen and considering its safety, HA can be used as an alternative to estrogen in patients who do not want to use estrogen. The available studies have several limitations, and the reporting of outcomes was considerably heterogeneous.
引用
收藏
页数:13
相关论文
共 38 条
[1]   Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy [J].
Alvisi, Stefania ;
Lami, Alessandra ;
Baldassarre, Maurizio ;
Lenzi, Jacopo ;
Mancini, Ilaria ;
Seracchioli, Renato ;
Meriggiola, Maria Cristina .
JOURNAL OF SEXUAL MEDICINE, 2022, 19 (05) :761-770
[2]   Vaginal Health in Menopausal Women [J].
Alvisi, Stefania ;
Gava, Giulia ;
Orsili, Isabella ;
Giacomelli, Giulia ;
Baldassarre, Maurizio ;
Seracchioli, Renato ;
Meriggiola, Maria Cristina .
MEDICINA-LITHUANIA, 2019, 55 (10)
[3]   The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society [J].
不详 .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (09) :976-992
[4]  
[Anonymous], 2003, Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommendations for clinical evaluation
[5]  
[Anonymous], 2016, Appendix E: case-control studies
[6]  
[Anonymous], 2016, The social care guidance manual process and methods [PMG10]. Appendix C: randomised controlled trials
[7]   Efficacy and tolerability of local estrogen therapy for urogenital atrophy [J].
Archer, David F. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2010, 17 (01) :194-203
[8]   Evaluation of the effect of multipoint intra-mucosal vaginal injection of a specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study [J].
Berreni, Nicolas ;
Salerno, Jennifer ;
Chevalier, Thierry ;
Alonso, Sandrine ;
Mares, Pierre .
BMC WOMENS HEALTH, 2021, 21 (01)
[9]   A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors [J].
Carter, Jeanne ;
Baser, Raymond E. ;
Goldfrank, Deborah J. ;
Seidel, Barbara ;
Milli, Lisania ;
Stabile, Cara ;
Canty, Jocelyn ;
Saban, Sally ;
Goldfarb, Shari ;
Dickler, Maura N. ;
Gardner, Ginger J. ;
Jewell, Elizabeth L. ;
Sonoda, Yukio ;
Kollmeier, Marisa A. ;
Alektiar, Kaled M. .
SUPPORTIVE CARE IN CANCER, 2021, 29 (01) :311-322
[10]   Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection [J].
Castelo-Branco, Camil ;
Biglia, Nicoletta ;
Nappi, Rossella E. ;
Schwenkhagen, Anne ;
Palacios, Santiago .
MATURITAS, 2015, 81 (04) :462-469